Profile data is unavailable for this security.
About the company
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
- Revenue in CAD (TTM)0.00
- Net income in CAD-2.62m
- Incorporated2004
- Employees--
- LocationClaritas Pharmaceuticals Inc4040 Civic Center Drive, Suite 200SAN RAFAEL 94903United StatesUSA
- Phone+1 (416) 362-4441
- Fax+1 (403) 266-8647
- Websitehttps://claritaspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Well Told Company Inc | -100.00bn | -100.00bn | 781.42k | -- | -- | -- | -- | -- | -- | -- | -- | -0.0053 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3492 | -- | 2.27 | -- | -- | -- | -- | -- | -- | -- |
| Hempshire Group Inc | 270.25k | -3.42m | 795.84k | -- | -- | -- | -- | 2.94 | -0.0429 | -0.0429 | 0.0034 | -0.003 | 0.1424 | 0.2852 | 29.30 | -- | -180.18 | -- | -288.91 | -- | 46.93 | -- | -1,265.05 | -- | 0.0712 | -21.61 | 1.61 | -- | -68.89 | -- | -200.59 | -- | -- | -- |
| Psybio Therapeutics Corp | 0.00 | -3.86m | 839.27k | 4.00 | -- | -- | -- | -- | -0.0331 | -0.0331 | 0.00 | -0.0181 | 0.00 | -- | -- | -- | -357.70 | -- | -- | -- | -- | -- | -- | -- | -- | -617.30 | -- | -- | -- | -- | 55.66 | -- | -- | -- |
| Lumiera Health Inc | 592.93k | -2.36m | 845.56k | -- | -- | -- | -- | 1.43 | -0.0139 | -0.0139 | 0.0035 | -0.0136 | 0.5096 | 2.13 | 11.78 | -- | -202.92 | -- | -- | -- | 13.17 | -- | -398.18 | -- | 0.0395 | -2.10 | -- | -- | 46.91 | -- | -188.58 | -- | -- | -- |
| Hill Inc | 2.16m | -1.91m | 902.77k | -- | -- | 0.8735 | -- | 0.4177 | -0.5883 | -0.5883 | 0.6665 | 0.3148 | 0.4461 | 54.88 | 5.54 | -- | -39.40 | -77.46 | -44.59 | -101.03 | 70.62 | 50.14 | -88.31 | -153.93 | 3.42 | -3.86 | 0.7205 | -- | -10.23 | 33.86 | 18.26 | -- | 16.21 | -- |
| Claritas Pharmaceuticals Inc | 0.00 | -2.62m | 957.75k | -- | -- | -- | -- | -- | -0.0852 | -0.204 | 0.00 | 0.1268 | 0.00 | -- | -- | -- | -17.49 | -33.39 | -51.79 | -39.16 | -- | -- | -- | -- | -- | 6.86 | 0.1409 | -- | -- | -- | 119.85 | -- | -- | -- |
| Waverley Pharma Inc | 542.61k | -1.10m | 1.08m | -- | -- | 5.62 | -- | 1.99 | -0.0203 | -0.0203 | 0.01 | 0.0036 | 0.2208 | 4.35 | 1.99 | -- | -44.66 | -22.36 | -136.53 | -33.74 | 29.75 | 13.38 | -202.32 | -83.43 | 0.1192 | -91.59 | 0.8555 | -- | -28.87 | -- | 16.63 | -- | -- | -- |
